Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide for Neoadjuvant Treatment of PPGL
NCT05885386Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in pheochromocytoma and Paraganglioma (PGL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of patients whose tumor change from unresectable to resectable tumor at Cycle 3. Status: unknown.
02
Drugs
temozolomide
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT05885386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885386.